Rob Meijer is CEO of Amphera BV. Amphera B.V., an advanced-clinical-stage biotechnology company, develops dendritic cell therapies for the treatment of cancer. Our lead indication is mesothelioma, a cancer of the lining of the lungs. MesoPher is autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.